Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

Shots:

• Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing modifiers targeting oncology & neurological disorders
• Genentech to get an exclusive WW license to develop & commercialize RNA splicing modifiers targeting neurodegenerative diseases and cancer and will be responsible for clinical & commercial activities            
• Skyhawk’s SkySTAR technology corrects the genetics of disease at the mRNA level in the nucleus of cells by integrating information from computational, kinetic, & structural models of RNA

Click here to read full press release/ article | Ref: PRNewswire | Image: Irish times